×
About 1,300 results

ALLMedicine™ Oral Medicine Center

Research & Reviews  360 results

World Workshop on Oral Medicine VII: Oral adverse effects to biologic agents in patient...
https://doi.org/10.1111/jop.13389
Journal of Oral Pathology & Medicine : Official Publicati... France K, Yogarajah S et. al.

Dec 2nd, 2022 - Biologic therapies are rapidly emerging as an effective therapy to treat autoimmune and other chronic diseases. The use of these agents is poorly characterized, resulting in a lack of guidance for dental practitioners. Case reports of oral adverse...

eHealth, teledentistry and health workforce challenges: results of a pilot project.
https://doi.org/10.1186/s12903-022-02603-6
BMC Oral Health; Németh O, Simon F et. al.

Dec 2nd, 2022 - In the twenty-first century, health systems have to cope with the challenges posed by their rapidly changing environment. Among these changes, the emergence of digital health solutions is an opportunity to make health systems better, but also a co...

Impact of medications on salivary flow rate in patients with xerostomia: a retrospectiv...
https://doi.org/10.1007/s00784-022-04717-1
Clinical Oral Investigations; Fortuna G, Whitmire S et. al.

Oct 22nd, 2022 - This study evaluates the impact of systemic medications and polypharmacy on unstimulated (UWS) and chewing-stimulated whole saliva (SWS) flow rates in patients with xerostomia. This cross-sectional multicenter study is based on data of patients re...

Sustained Delivery of Methylsulfonylmethane from Biodegradable Scaffolds Enhances Effic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558569
International Journal of Nanomedicine; Guo Y, Li P et. al.

Oct 18th, 2022 - As a popular dietary supplement containing sulfur compound, methylsulfonylmethane (MSM) has been widely used as an alternative oral medicine to relieve joint pain, reduce inflammation and promote collagen protein synthesis. However, it is rarely u...

Predictive Value of GOCCLES® Device for Early Diagnosis of Oral Potentially Malignant Disorders
https://clinicaltrials.gov/ct2/show/NCT05562375

Oct 4th, 2022 - The main objective of this study is to establish GOCCLES® autofluorescence method predictive value in early diagnostic of malignant oral disorders and/or potentially malignant oral cavities. The secondary objectives are comparing the match in zone...

see more →

Guidelines  4 results

MASCC/ISOO expert opinion on the management of oral problems in patients with advanced ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633484
Supportive Care in Cancer : Official Journal of the Multi... Jones JA, Chavarri-Guerra Y et. al.

Jun 19th, 2022 - The Palliative Care Study Group in conjunction with the Oral Care Study Group of the Multinational Association for Supportive Care in Cancer (MASCC) formed a sub-group to develop evidence-based guidance on the management of common oral problems in...

Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinio...
https://doi.org/10.1016/j.bbmt.2020.07.001
Biology of Blood and Marrow Transplantation : Journal of ... Bar M, Ott SM et. al.

Jul 13th, 2020 - Bone health disturbances commonly occur after hematopoietic cell transplantation (HCT) with loss of bone mineral density (BMD) and avascular necrosis (AVN) foremost among them. BMD loss is related to pretransplantation chemotherapy and radiation e...

Classifying orofacial pains: a new proposal of taxonomy based on ontology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383028
Journal of Oral Rehabilitation; Nixdorf DR, Drangsholt MT et. al.

Aug 19th, 2011 - We propose a new taxonomy model based on ontological principles for disorders that manifest themselves through the symptom of persistent orofacial pain and are commonly seen in clinical practice and difficult to manage. Consensus meeting of eight ...

The dental treatment of patients with joint replacements: a position paper from the Ame...
https://doi.org/10.14219/jada.archive.2010.0255
Journal of the American Dental Association (1939); Little JW, Jacobson JJ et. al.

Jun 3rd, 2010 - In February 2009, the American Academy of Orthopaedic Surgeons (AAOS) published an information statement in which the organization "recommends that clinicians consider antibiotic prophylaxis [AP] for all total joint replacement patients prior to a...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  89 results

Predictive Value of GOCCLES® Device for Early Diagnosis of Oral Potentially Malignant Disorders
https://clinicaltrials.gov/ct2/show/NCT05562375

Oct 4th, 2022 - The main objective of this study is to establish GOCCLES® autofluorescence method predictive value in early diagnostic of malignant oral disorders and/or potentially malignant oral cavities. The secondary objectives are comparing the match in zone...

Comparative Efficacy of Platelet Rich Plasma and Dry Needling in Management of Anterior Disc Displacement of Temporomandibular Joint
https://clinicaltrials.gov/ct2/show/NCT05532098

Sep 8th, 2022 - Study Design: Randomized clinical trial Study Duration: This study will be completed in 1 year 3 months (3 months for patient recruitment, 9 months for study including treatment and follow up and 3 months for data compilation). Population: Patient...

The Prevalence of Gingival Pigmentation Among a Sample of Adult Egyptian Population.
https://clinicaltrials.gov/ct2/show/NCT05453890

Jul 12th, 2022 - Dental patients will be recruited in a consecutive manner from the diagnostic center, Faculty of Dentistry, Cairo University. Medical history will be taken and patients with certain diseases as Addison's disease, Albright's syndrome, Hereditary he...

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
https://clinicaltrials.gov/ct2/show/NCT01639508

Jun 23rd, 2022 - The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study look...

The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome
https://clinicaltrials.gov/ct2/show/NCT05309070

May 25th, 2022 - The research will include patients who come to the Department of Oral Medicine at the Faculty of Dentistry in Zagreb, and who have been diagnosed with burning mouth syndrome. It is planned to gather a total of 60 patients, 30 patients in the treat...

see more →

News  52 results

Using Multidisciplinary Care to Optimize Outcomes in GVHD
https://www.onclive.com/view/using-multidisciplinary-care-to-optimize-outcomes-in-gvhd

Oct 11th, 2022 - Transcript: Corey Cutler, MD, MPH, FRCPC: It takes a village, obviously, to treat both acute and chronic graft-vs-host disease [GVHD]. Linda, do you want to tell us any pearls you might have on employing this multidisciplinary team to treat acute...

New Nonstatin Cholesterol Lowering Drugs: How to Use Them
https://www.medscape.com/viewarticle/980362

Sep 27th, 2022 - This transcript has been edited for clarity. I'm Dr Neil Skolnik, and today we are going to talk about the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclero...

FDA Approves 'Rapid-Acting' Oral Drug for Major Depression
https://www.medscape.com/viewarticle/979568

Aug 22nd, 2022 - The US Food and Drug Administration (FDA) has approved the first oral N-methyl D-aspartate (NMDA) receptor antagonist for the treatment of major depressive disorder (MDD) in adults, its manufacturer has announced. Auvelity (Axsome Therapeutics) is...

Frontline Treatment Options for Chronic GVHD
https://www.onclive.com/view/frontline-treatment-options-for-chronic-gvhd

Apr 4th, 2022 - Transcript: Yi-Bin Chen, MD: Many of the patients I see in my clinic are afflicted with chronic graft-vs-host disease, and it’s the most important determinant of long-term quality of life. When we talk about chronic graft-vs-host disease in studi...

Pfizer Says COVID-19 Pill Near 90% Effective in Final Analysis
https://www.medscape.com/viewarticle/964750

Dec 14th, 2021 - NEW YORK (Reuters) - Pfizer Inc on Tuesday said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effecti...

see more →

Patient Education  5 results see all →